Targeting specific potassium channels to help treat Alzheimer's disease
Targeting Kv1.3 potassium channels for neuro-immunomodulation in Alzheimer's Disease
This study is looking at how stopping certain channels in brain cells might help reduce inflammation and slow down the damage caused by Alzheimer's disease, with hopes that this could lead to new treatments for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10813840 on NIH RePORTER |
What this research studies
This research investigates how blocking Kv1.3 potassium channels can influence immune responses in the brain, particularly in the context of Alzheimer's disease. By focusing on the role of these channels in pro-inflammatory immune cells, the study aims to understand how their inhibition might slow down neurodegeneration. The researchers will conduct experiments using animal models to explore the effects of Kv1.3 blockers on immune signaling pathways and neuronal health. The ultimate goal is to establish a foundation for future clinical applications in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that slow the progression of Alzheimer's disease and improve patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting similar immune pathways in neurodegenerative diseases, suggesting potential for success in this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Rangaraju, Srikant — Yale University
- Study coordinator: Rangaraju, Srikant
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.